TG Therapeutics reported $594M in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850M in 2026. Click here ...
1d
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Power reported total global revenue for 2025 of $616 million, with $594 million in U.S. BRIUMVI net product revenue and $12.8 million in sales to Neuraxpharm. Quarterly net income was $23 million, ...
The company said a spin-off would occur after a $6 billion merger with fusion energy firm TAE Technologies.
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...
A demographic transformation in Africa has the potential to alter the world order Last November, the global population reached a significant milestone of 8 billion. More recently, in April, India ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results